Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: Insights from PARADIGM-HF
Journal article
Jhund, Pardeep S., Fu, Michael, Bayram, Edmundo, Chen, -Huan Chen, Negrusz-Kawecka, Marta, Rosenthal, Arvo, Desai, Akshay S., Lefkowitz, Martin P., Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R., McMurray, John J. V. and Packer, Milton. (2015). Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: Insights from PARADIGM-HF. European Heart Journal. 36(38), pp. 2576 - 2584. https://doi.org/10.1093/eurheartj/ehv330
Authors | Jhund, Pardeep S., Fu, Michael, Bayram, Edmundo, Chen, -Huan Chen, Negrusz-Kawecka, Marta, Rosenthal, Arvo, Desai, Akshay S., Lefkowitz, Martin P., Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R., McMurray, John J. V. and Packer, Milton |
---|---|
Abstract | Background: The age at which heart failure develops varies widely between countries and drug tolerance and outcomes also vary by age. We have examined the efficacy and safety of LCZ696 according to age in the Prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin converting enzyme inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF). Methods: In PARADIGM-HF, 8399 patients aged 18–96 years and in New York Heart Association functional class II–IV with an LVEF ≤40% were randomized to either enalapril or LCZ696. We examined the pre-specified efficacy and safety outcomes according to age category (years): < 55 (n = 1624), 55–64 (n = 2655), 65–74 (n = 2557), and ≥75 (n = 1563). Findings: The rate (per 100 patient-years) of the primary outcome of cardiovascular (CV) death or heart failure hospitalization (HFH) increased from 13.4 to 14.8 across the age categories. The LCZ696:enalapril hazard ratio (HR) was < 1.0 in all categories (P for interaction between age category and treatment = 0.94) with an overall HR of 0.80 (0.73, 0.87), P < 0.001. The findings for HFH were similar for CV and all-cause mortality and the age category by treatment interactions were not significant. The pre-specified safety outcomes of hypotension, renal impairment and hyperkalaemia increased in both treatment groups with age, although the differences between treatment (more hypotension but less renal impairment and hyperkalaemia with LCZ696) were consistent across age categories. Interpretation: LCZ696 was more beneficial than enalapril across the spectrum of age in PARADIGM-HF with a favourable benefit–risk profile in all age groups. |
Keywords | heart failure; neprilysin; receptors; angiotensin; age |
Year | 2015 |
Journal | European Heart Journal |
Journal citation | 36 (38), pp. 2576 - 2584 |
Publisher | Oxford University Press |
ISSN | 0195-668X |
Digital Object Identifier (DOI) | https://doi.org/10.1093/eurheartj/ehv330 |
Scopus EID | 2-s2.0-84947748008 |
Open access | Open access |
Page range | 2576 - 2584 |
Research Group | Mary MacKillop Institute for Health Research |
Publisher's version | |
Additional information | © The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
Place of publication | United Kingdom |
https://acuresearchbank.acu.edu.au/item/85xzq/efficacy-and-safety-of-lcz696-sacubitril-valsartan-according-to-age-insights-from-paradigm-hf
Download files
137
total views81
total downloads6
views this month2
downloads this month